Your browser doesn't support javascript.
loading
Amplification of tumor antigen presentation by NLGplatin to improve chemoimmunotherapy.
Zhu, Yong; Xing, Lei; Zheng, Xiao; Yang, Chen-Xi; He, Yu-Jing; Zhou, Tian-Jiao; Jin, Qing-Ri; Jiang, Hu-Lin.
Affiliation
  • Zhu Y; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Xing L; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China; Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, China; Jiangsu Key Laboratory of Drug Screening, China Pharma
  • Zheng X; State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
  • Yang CX; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • He YJ; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Zhou TJ; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Jin QR; Key Laboratory of Applied Technology on Green-Eco-Healthy Animal Husbandry of Zhejiang Province, College of Animal Science and Technology, Zhejiang A&F University, Lin'an, Zhejiang 311300, China. Electronic address: jin@zafu.edu.cn.
  • Jiang HL; State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China; Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, China; Jiangsu Key Laboratory of Drug Screening, China Pharma
Int J Pharm ; 573: 118736, 2020 Jan 05.
Article in En | MEDLINE | ID: mdl-31756442
ABSTRACT
Oxaliplatin is a chemotherapeutic agent widely used in cancer treatment whereas its immunosuppressive effect hinders the progress of immunotherapy. Here we have synthesized a new compound NLGplatin constructed by combining oxaliplatin (OXA) and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG919. The NLGplatin acquires chemotherapeutic properties of OXA and can activate the immune system, and also retains the ability to inhibit IDO enzyme activity without affecting the proliferation of immune cells. This difunctional drug has a great potential to achieve effective cancer chemoimmunotherapy.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Isoindoles / Oxaliplatin / Imidazoles / Immunotherapy / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Int J Pharm Year: 2020 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Isoindoles / Oxaliplatin / Imidazoles / Immunotherapy / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Int J Pharm Year: 2020 Document type: Article Affiliation country: China